{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:03:42Z","timestamp":1773313422789,"version":"3.50.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p>Opportunistic infections are those that are either more frequent or more severe as a result of the patient\u2019s immunosuppressed condition. Opportunistic infections are, of course, the distinguishing feature of HIV infection, and they can be the cause of serious morbidity and even mortality. Some opportunistic infections can be prevented by vaccination, for example, pneumococcal infection, meningococcal infection, influenza, hepatitis A and B, and varicella. Other major opportunistic infections require prophylactic antibiotics or antiviral medications. In obstetric patients, pneumocystis infections and toxoplasmosis are most effectively prevented by the administration of trimethoprim\u2010sulfamethoxazole. The most effective agents for prevention of reactivation of tuberculosis are isoniazid, rifampin, and rifapentine. Fluconazole is of value in preventing cryptococcal infection and candidiasis. Acyclovir, valacyclovir, and famiclovir are effective in preventing recurrent outbreaks of herpes simplex virus. Ultimately; however, the best way to prevent opportunistic infections is to treat the patient with highly active antiretroviral agents and restore her immune competence.<\/jats:p>","DOI":"10.1097\/grf.0000000000000483","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T10:41:40Z","timestamp":1566297700000},"page":"816-822","source":"Crossref","is-referenced-by-count":9,"title":["Prevention of Opportunistic Infections in Women With HIV Infection"],"prefix":"10.1097","volume":"62","author":[{"given":"PATRICK","family":"DUFF","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-20230911","article-title":"Prophylaxis against pneumococcal infections","author":"Moumne","year":"2019","journal-title":"Clin Obstet Gynecol"},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMra1509044","article-title":"Maternal immunization","volume":"376","author":"Omer","year":"2017","journal-title":"N Engl J Med"},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jama.2015.17844","article-title":"Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth","volume":"315","author":"Molgaard-Nielsen","year":"2016","journal-title":"JAMA"},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/infdis\/169.6.1338","article-title":"Recurrence and resistance patterns of herpes simplex virus following cessation of greater than or equal to 6 years of chronic suppression with acyclovir","volume":"169","author":"Fife","year":"1994","journal-title":"J Infect Dis"},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1471-0528.1998.tb10086.x","article-title":"A randomized placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection","volume":"105","author":"Brocklehurst","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"R9-20230911","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0029-7844(96)00261-X","article-title":"Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis","volume":"88","author":"Randolph","year":"1996","journal-title":"Obstet Gynecol"},{"key":"R10-20230911","first-page":"CD004946","article-title":"Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection","volume":"1","author":"Hollier","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-20230911","first-page":"1","volume":"64","year":"2015","journal-title":"MMRW"},{"key":"R13-20230911","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1056\/NEJMe1901656","article-title":"Ending tuberculosis through prevention","volume":"380","author":"Saunders","year":"2019","journal-title":"N Engl J Med"},{"key":"R14-20230911","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T08:17:27Z","timestamp":1694420247000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000483","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}